Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Day (2026)
103 slides from Diasorin's investor day presentation, 2026
Slide 1: 2026 Investor Day
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by Diasorin S.p.A. (“Diasorin” or the “Co
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Welcome
O1 WELCOME Michele Denegri Chairman
Slide 5: Diasorin
6) Diasorin
Slide 6: Agenda
Agenda Strategic Overview Immunodiagnostics Molecular Diagnostics Licensed Technologies ESG & Financials Key Takeaways Q&A
Slide 7: Strategic Overview
02 STRATEGIC OVERVIEW Carlo Rosa
Slide 8: We have achieved significant progress since our last Investor Day
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin uniqueness We have achieved significant progress since our last Investor Day TODAY U.S. accounts for Expanded our presence in the U.S. market ~50% of our 40% of global IVD market Total Revenue Molecular is our Gained access to a unique multip
Slide 9: IVD Market at a glance
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market IVD Market at a glance The In Vitro Diagnostics (IVD) market remains one of the most dynamic and resilient segments within global healthcare. Following significant expansion during the COVID-19 pandemic, the global IVD market is now undergoing a per
Slide 10: 5 Macro Trends in Healthcare reshaping Diagnostics
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends 5 Macro Trends Demographic shift Aging populations & chronic disease burden in Healthcare Consolidation in the Core Labs reshaping High-throughput automation & workflow integration Diagnostics Decentralization Lab to Point-Of-Care migration
Slide 11: 5 Macro Trends in Healthcare reshaping Diagnostics
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends 5 Macro Trends in Healthcare reshaping Diagnostics Demographic shift Consolidation in the Core Labs Aging populations & chronic disease burden High-throughput automation Decentralization & workflow integration 1 in 6 people globally over 60
Slide 12: 5 Macro Trends in Healthcare reshaping Diagnostics
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends 5 Macro Trends in Healthcare reshaping Diagnostics Value-Based Care Precision Medicine Regional Dynamics and Complementary United States Diagnostics (CDx) Healthcare spending PAMA recalibration reduced Medicare rates 10- pressure & Value-Ba
Slide 13: Diasorin is well positioned to address key sector trends
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends Diasorin is well positioned to address key sector trends DEMOGRAPHIC SHIFT CONSOLIDATION DECENTRALIZATION VALUE-BASED CARE PRECISION MEDICINE AND ❌ Cancer ✔️ NEW ✔️ LIAISON NES ✔️ LIAISON PLEX COMPLEMENTARY ❌ Alzheimer LIAISON XL DIAGNOSTIC
Slide 14: IVD players divided in 2 groups
02 | STRATEGIC OVERVIEW Specialist positioning | Competitors IVD players divided in 2 groups Multi-segment driven by Clinically specialized across technologies Total Lab Automation (TLA) with leadership positions Bacteriology and Immunoassay Microbiology Clinical Chemistry Coagulation LC-Mass-Spec H
Slide 15: Diasorin unique positioning as a Specialist in diagnostics
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin uniqueness Diasorin unique positioning: what does it mean to be a Specialist in diagnostics today Diasorin stands as a unique company EXAMPLES because: H. Pylori Ag, MeMed, C. auris PCR, INFECTIOUS DISEASES It doesn’t play in a unique clinica
Slide 16: Diasorin's Unique Specialist Positioning
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin’s Unique Specialist Positioning Diasorin’s Unique Specialist Positioning An integrated Specialty Portfolio built around high-value indications, targeted settings, and clinical workflow fit Immunodiagnostics Molecular Diagnostics Licensed Tech
Slide 17: Looking Forward to 2030: what do we commit to deliver
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin uniqueness Looking Forward to 2030: what do we commit to deliver Immunodiagnostics Molecular Diagnostics Licensed Technologies >20 new specialty assays Increasing competitiveness of New contracts with Diagnostic and LIAISON NES Biopharma part
Slide 18: Immunodiagnostics
03 IMMUNODIAGNOSTICS Chen Even
Slide 19: Immunology Market Size and Clinical Areas
03 | IMMUNODIAGNOSTICS Market Immunology Market Size and Clinical Areas Other Applications Newborn Screening Drug Monitoring & Testing Infectious Diseases Cardiology GLOBAL MARKET - IMMUNOASSAYS ~18 €/bn Allergy Oncology Hepatitis and Retrovirus Focus Clinical areas for Diasorin Future areas of deve
Slide 20: Broadening the distance to competition
03 | IMMUNODIAGNOSTICS Menu Comparison Broadening the distance to competition Differentiating High-routine tests & High-Volume Specialties 86 63 46 Diasorin Immunoassay tests 32 Tests of the main competitor within the area “ “ We have the broadest immunoassay menu available on the market 20
Slide 21: Products
PRODUCTS
Slide 22: Latent Tuberculosis
03 | IMMUNODIAGNOSTICS Products | Latent Tuberculosis Latent Tuberculosis
Slide 23: Latent Tuberculosis - Market
03 | IMMUNODIAGNOSTICS Products | Latent Tuberculosis Latent Tuberculosis - Market Tuberculosis Active TB Characteristics • > 10 million active cases globally • TB is actively spreading • Symptomatic and contagious • Testing through NAAT, chest X-Ray, sputum ~2 bn People infected with • Often deadly
Slide 24: Latent Tuberculosis – Full automation and improved efficiency
03 | IMMUNODIAGNOSTICS Products | Latent Tuberculosis Latent Tuberculosis – Full automation and improved efficiency Advancing workflow automation Inpeco partnership move QuantiFERON and LIAISON towards a full Addressing the need to improve pre-analytical steps in labs ecosystem solution QIAGEN fully
Slide 25: Our competitive advantage
03 | IMMUNODIAGNOSTICS Products | Latent Tuberculosis Our competitive advantage Tubes for CD4 and CD8 Market leader in TB QFT-TB brand recognized Broadest claims for antigen testing segment as WHO Gold-Standard patient population COMPETITIVE ADVANTAGES TO FACE POTENTIAL COMPETITION ON TB 25
Slide 26: Gastrointestinal
03 | IMMUNODIAGNOSTICS Products | Gastrointestinal Gastrointestinal
Slide 27: GI Health: Serving Dx Needs for Gastroenterologists
03 | IMMUNODIAGNOSTICS Products | Gastrointestinal GI Health: Serving Dx Needs for Gastroenterologists 27
Slide 28: Diasorin GI Immunodiagnostics Panel
03 | IMMUNODIAGNOSTICS Products | Gastrointestinal Diasorin GI Immunodiagnostics Panel BROAD, INTEGRATED GI MENU NEAR-TERM INNOVATION AND NEXT-WAVE (8 LIAISON TESTS) PIPELINE (2026-2027) Covers inflammation, infectious diseases, pancreatic LIAISON Q.S.E.T. Quick Pick – home stool collection kit: mar
Slide 29: Calprotectin – Market overview
03 | IMMUNODIAGNOSTICS Products | Calprotectin Calprotectin – Market overview Rising prevalence of 5-10% of the world population has IBS chronic GI diseases (IBD, IBS), with increasing burden of gastrointestinal Calprotectin is the key infections ~1% of the western world population has IBD test to d
Slide 30: Calprotectin HD for enhancing diagnostic power
03 | IMMUNODIAGNOSTICS Products | Calprotectin Gastrointestinal – Calprotectin HD for enhancing diagnostic power THE CHALLENGE THE SOLUTION IBD* DIAGNOSIS – AS IS Diagnosis complexity: differentiation Limited specificity (“grey zone”): from diseases with similar presentation Moderate calprotectin el
Slide 31: Stool and Blood biomarkers inform IBD management
03 | IMMUNODIAGNOSTICS Products | Calprotectin Gastrointestinal - Stool and Blood biomarkers inform IBD management across patient journey 5 key phases of the patient journey with IBD: ACTIVITY Diagnosis A. IBD vs IBS Diagnosis Prediction of treatment response B. Prediction of treatment response Asse
Slide 32: Hypertension
03 | IMMUNODIAGNOSTICS Products | Hypertension Hypertension
Slide 33: Hypertension – a new guideline for primary Aldosteronism
03 | IMMUNODIAGNOSTICS Products | Hypertension Hypertension – a new guideline for primary Aldosteronism Including Diasorin established cutoffs Primary Aldosteronism (PA): The opportunity: current market scenario a changing clinical environment Severely underdiagnosed form of Hypertension: only 0.5-2
Slide 34: Hypertension – a new guideline for primary Aldosteronism
03 | IMMUNODIAGNOSTICS Products | Hypertension Hypertension – a new guideline for primary Aldosteronism Including Diasorin established cutoffs DIASORIN LEADING THE WAY TOTAL ACCESSIBLE MARKET (TAM) Potential future TAM Current TAM Recommended cut-off for ARR reflects Diasorin’s Full adoption on new
Slide 35: MeMed
03 | IMMUNODIAGNOSTICS Products | MeMed MeMed
Slide 36: MeMed – Target and initiatives 2026-2030 (US focus)
03 | IMMUNODIAGNOSTICS Products | MeMed Memed – Target and initiatives 2026-2030 (US focus) 2026-2030 by 2030 NEW CUSTOMERS ~50 per year TOTAL CUSTOMERS TARGET >250 = 1/3 of Diasorin’s U.S. Hospital Targets MeMed BV guidance reduced unnecessary antibiotic prescriptions in viral patients by 52% (25%
Slide 37: Systems
SYSTEMS
Slide 38: LIAISON XL Evolution
03 | IMMUNODIAGNOSTICS Systems LIAISON XL Evolution TODAY H1’27 Compact size. Expanded power. Fully Integrated. Maximum flexibility in every configuration Expanded capacity without increasing footprint Immediate access to a complete reagent menu Full compatibility with existing Total Lab Automation
Slide 39: Increased Sample Capacity and Accelerated workflow
03 | IMMUNODIAGNOSTICS Systems Increased Sample Capacity and Accelerated workflow Automated ID & De-capping No Buffer Preparation Need Smart tube handling Improved Walk-away time, safety and workflow efficiency Optimized workflow & connectivity Automated Flexible installation Throughput improvement
Slide 40: U.S. Hospitals Strategy
U.S. HOSPITALS STRATEGY
Slide 41: U.S. Hospitals Strategy
03 | IMMUNODIAGNOSTICS U.S. Hospitals Strategy U.S. Hospitals Strategy START PHASE 1 PHASE 2 PHASE 3 2019 2020-2022 2023-2026 2027-2030 TOTAL HOSPITALS ~150 ~300 ~600 ~900 NEW HOSPITALS Identification of +150 +300 +300 2,200 hospitals (Addressable Continue penetration and focus market) on add-on spe
Slide 42: Future Opportunities
FUTURE OPPORTUNITIES
Slide 43: Autoimmunity
03 | IMMUNODIAGNOSTICS Future Opportunities | Autoimmunity Autoimmunity
Slide 44: Autoimmunity market
03 | IMMUNODIAGNOSTICS Future Opportunities | Autoimmunity Autoimmunity market Specialty Autoimmune testing Presenting the best opportunity for expansion in an untapped area of Immunodiagnostic testing Global market1: 45% high-volume; 1.3 €/bn 55% specialty Size and 63% in Europe and NA, with 4
Slide 45: Autoimmunity – Diasorin positioning
03 | IMMUNODIAGNOSTICS Future Opportunities | Autoimmunity Autoimmunity – Diasorin positioning Autoimmunity testing is evolving from a niche specialty area into a core component of centralized laboratory workflows Diasorin recognized Existing major Total Lab by leading TLA players Automation (TLA) a
Slide 46: Complementary Diagnostics
03 | IMMUNODIAGNOSTICS Future Opportunities | Complementary Diagnostics Complementary Diagnostics
Slide 47: Diagnostics are no longer support – they are the decision
03 | IMMUNODIAGNOSTICS Future Opportunities | Complementary Diagnostics Diagnostics are no longer support – they are the decision PRECISION MEDICINE | STRATEGIC CONTEXT Precision medicine (companion and complementary diagnostics) is redefining how drugs reach patients—and how every clinical dollar i
Slide 48: Half the precision medicine wave lies outside oncology
03 | IMMUNODIAGNOSTICS Future Opportunities | Complementary Diagnostics Half the precision medicine wave lies outside oncology – and we have the first proof points to act on it STRATEGIC OPPORTUNITY | NON-ONCOLOGY EXPANSION Precision medicine is mainstream in oncology—but 50% of biomarker-driven dru
Slide 49: Key Takeaways on Immunodiagnostics
03 | IMMUNODIAGNOSTICS Key Takeaways Key Takeaways on Immunodiagnostics Strong positioning Differentiated competitive in large/attractive market positioning/menu leadership Strategic exposure Broadest immunoassay menus in the market Focused portfolio targeting high-value segments Clear edge in high-
Slide 50: Molecular Diagnostics
04 MOLECULAR DIAGNOSTICS Angelo Rago Giulia Amicarelli
Slide 51: Macro trends in Healthcare: impact on Molecular Diagnostics
04 | MOLECULAR DIAGNOSTICS Market Macro trends in Healthcare: impact on Molecular Diagnostics DRIVERS NEEDS WINNING PROFILE Healthcare Pressures Market Dynamics What Will Win • Aging populations & rising chronic • Increased demand for complex • Targeted and highly specialized disease burden diagnosi
Slide 52: Multiplexing capabilities
04 | MOLECULAR DIAGNOSTICS Market | Multiplexing & Throughput Molecular ID Diagnostics requires technologies specific to the needs On-demand testing Batch testing Low/Medium Throughput Multiplexing High Throughput Multiplexing >10 plex Diasorin is leading the way in Diagnostic Multiplexing capabilit
Slide 53: Multiplexing capabilities
04 | MOLECULAR DIAGNOSTICS Market | Multiplexing & Throughput Molecular ID Diagnostics requires technologies specific to the needs On-demand testing Batch testing Low/Medium Throughput Multiplexing High Throughput Multiplexing >10 plex • Hospital Labs • Reference Labs • Reference Labs • National Lab
Slide 54: Integrated Delivery Networks and where ID diagnostics is performed
04 | MOLECULAR DIAGNOSTICS Market | Healthcare System | Acute & Non-Acute Segment Integrated Delivery Networks and where ID diagnostics is performed A vertical system integrated by EMR, quality metrics, and payers' contracts Hospital ADMISSION Hub & Spoke Labs, ED, wards, admission Units 10K Quick d
Slide 55: Integrated Delivery Networks and physicians' acquisition
04 | MOLECULAR DIAGNOSTICS Market | Healthcare System | Acute & Non-Acute Segment Integrated Delivery Networks and physicians' acquisition A vertical system integrated by EMR, quality metrics, and payers' contracts Hospital IDNs ACQUIRE PHYSICIANS & URGENT CARES TO: Hub & Spoke Labs, ED, wards, admi
Slide 56: Decentralized (CLIA-waived) segment: $1.5B Opportunity
04 | MOLECULAR DIAGNOSTICS Market | Healthcare System | Acute & Non-Acute Segment Decentralized (CLIA-waived) segment: $1.5B Opportunity 90% of testing is Respiratory 30% decentralized ID testing is Molecular 10K ~4M Antigen 70% tests Acute Molecular 30% ~$1.5B 30K ~30M tests Non-Acute ~26M tests 18
Slide 57: Diasorin Portfolio positioning
Diasorin Portfolio positioning
Slide 58: Diasorin portfolio positioning, in the IDN evolving landscape
04 | MOLECULAR DIAGNOSTICS Market | Healthcare System | Acute & Non-Acute Segment Diasorin portfolio positioning, in the IDN evolving landscape To win in IDN accounts, our diagnostic platform must be enablers of their objectives. IDNs are evolving their view of diagnostics from cost centers to lever
Slide 59: LIAISON NES
04 | MOLECULAR DIAGNOSTICS LIAISON NES LIAISON NES
Slide 60: LIAISON NES is designed to fit the Point-of-Care segment
04 | MOLECULAR DIAGNOSTICS LIAISON NES LIAISON NES is designed to fit the Point-of-Care segment ASSAY MENU ✓ ~15 min Time to Result ✓ Highly automated FDA-Cleared Menu ✓ Enhanced connectivity ✓ Streamlined implementation LIAISON NES ✓ Touchscreen FLU A/B, RSV & COVID-19 ✓ Room temperature storage I
Slide 61: LIAISON NES is enabling simplicity by focusing on user needs
04 | MOLECULAR DIAGNOSTICS LIAISON NES LIAISON NES is enabling simplicity by focusing on user needs 3-step workflow Seamless connectivity (Room temperature (Wi-Fi/ethernet, laboratory reagents) information system LIS, cloud) Lab-quality performance ~15-minute time to result Using real-time RT-PCR (r
Slide 62: LIAISON NES is enabling simplicity by focusing on user needs
04 | MOLECULAR DIAGNOSTICS LIAISON NES LIAISON NES is enabling simplicity by focusing on user needs BENCH SPACE PORTABLE STORAGE STEPS TO SET-UP AMPLIFICATION MULTIPLEXING VISUALIZE CTS FRONT WIDTH DIMS & A TEST TIME AND PCR CURVES WEIGHTS LIAISON NES Y 11.5 cm Launched in 2026 Room Temp 7 16.5 min
Slide 63: LIAISON NES Go-To-Market
04 | MOLECULAR DIAGNOSTICS LIAISON NES LIAISON NES Go-To-Market Leveraging Direct Sales force and Distribution 10K Acute 30K Non-Acute 183K Commercial execution via the multiplier force of distribution 63
Slide 64: The Critical Gap in Sexually Transmitted Infections and Women's Health
04 | MOLECULAR DIAGNOSTICS LIAISON NES The Critical Gap in Sexually Transmitted Infections and Women’s Health STI diagnostics remain lab-dependent; clinicians cannot act during the patient visit THE PROBLEMS THE OPPORTUNITY DIMENSION OF THE PROBLEMS Hours to Days 2.5M+ Annual STI Cases Results from
Slide 65: Future Potential Market Opportunity
04 | MOLECULAR DIAGNOSTICS LIAISON NES Future Potential Market Opportunity CT/NG 465 $/mln 2030 Limited product CT/NG/TV 160 $/mln 2030 availability today, mostly represented Vaginitis 360 $/mln 2030 by highly centralized testing Lesion Panel 75 $/mln 2030 Extragenital 70 $/mln 2030 Out of ~ 1 $/bn
Slide 66: LIAISON PLEX
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX LIAISON PLEX
Slide 67: The right test for the right patient: LIAISON PLEX
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX The right test for the right patient: LIAISON PLEX ASSAY MENU FDA-Cleared Menu LIAISON PLEX Respiratory Flex Assay ✓ Flex Testing LIAISON PLEX Gram-Positive Blood Culture Assay ✓ Random access ✓ Sample-to-answer workflow LIAISON PLEX Gram-Negative Blood Cultur
Slide 68: Syndromic Technologies Portfolio Assessment, USA
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Syndromic Technologies Portfolio Assessment, USA US Syndromic Multiplex Diagnostics Market 2026 estimate 10K Acute 30K ~1.2 $/bn U.S. TAM Non-Acute ~5% CAGR 183K 68
Slide 69: Traditional syndromic testing is under pressure
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Traditional syndromic testing is under pressure Financial and Reimbursement Challenges Shifting reimbursement models, tighter budgets, and policy uncertainty require every test to 10 plex >10 plex demonstrate clear clinical and economic impact. Multiplexing ca
Slide 70: Diasorin's Differentiation
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Diasorin’s Differentiation Competition Diasorin LIAISON PLEX Vendor Defined Fixed Panels Patient Focused Flexible Panels Actionable results focused on Broad coverage for higher probability pathogens immunocompromised and high-acuity inpatients Aligned with cli
Slide 71: Example of LIAISON PLEX RSP Flex at a Primary U.S. Hospital System
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Example of LIAISON PLEX RSP Flex at a Primary U.S. Hospital System Respiratory Pathogen PCR Respiratory Pathogen PCR FLU/RSV/SARS-CoV- Bordetella PCR Mycoplasma & Chlamydia Panel Panel (w/o COVID/FLU/RSV) 2/Rhinovirus PCR Pneumoniae PCR ADENOVIRUS (A,B,C,D,E,F
Slide 72: Example of Gastrointestinal Syndromic testing based on Clinical Need
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Example of Gastrointestinal Syndromic testing based on Clinical Need Community Acquired Diarrhea Hospital Acquired infections Immuno-compromised Outbreak Investigations • Norovirus • Norovirus •Norovirus • Salmonella spp. • Norovirus • Salmonella spp. •C. diff
Slide 73: Gastrointestinal - Why the coverage gap exists
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Gastrointestinal - Why the coverage gap exists It is not about number of targets: the pathogens chosen determine clinical reach Legend: Bacteria Viruses Parasites Competitor 1 Competitor 2 LIAISON PLEX GI Flex 11 targets 11 targets Choose 11 targets Campylobac
Slide 74: Flexibility and Customization maximize effectiveness
04 | MOLECULAR DIAGNOSTICS LIAISON PLEX Flexibility and Customization maximize effectiveness VOLUME-WEIGHTED COVERAGE Across all 8 clinical scenarios, weighted by avg weekly volume LIAISON PLEX (Base 11) 73% Competitor 1 (11) 33% Competitor 2 (11) 10% THE COVERAGE FOOTPRINT LIAISON PLEX: balanced fo
Slide 75: Diagnostic stewardship
Diagnostic stewardship
Slide 76: Diasorin's Solution
04 | MOLECULAR DIAGNOSTICS DIAGNOSTIC STEWARDSHIP Diasorin’s Solution CLIA-Waived 4-plex FluAB, RSV & COVID-19 LIAISON NES and ER Onsite Testing LIAISON PLEX 4-plex RSP Flex are substantially equivalent as per If more testing needed the study outcome Testing complete reported in the 510(k) Visits ho
Slide 77: LIAISON MDX Plus
04 | MOLECULAR DIAGNOSTICS LIAISON MDX Plus LIAISON MDX Plus* * Launch in H1’27
Slide 78: LIAISON MDX and MDX Plus
04 | MOLECULAR DIAGNOSTICS LIAISON MDX Plus LIAISON MDX and MDX Plus ✓ Sample-to-answer ASSAY MENU ✓ Scalable ✓ CLIA moderate FDA- cleared Menu ✓ IVD and Open mode Simplexa HSV1&2 Direct capabilities ✓ Differentiated Menu Simplexa VZV Swab Direct ✓ No need for extraction Simplexa VZV CSF Direct Simp
Slide 79: Targeted Technologies Market Size, USA
04 | MOLECULAR DIAGNOSTICS LIAISON MDX Plus Targeted Technologies Market Size, USA US Target Diagnostics Market 2026 estimate ~5.1 $/bn 10K US TAM Acute 30K 0.9 $/bn 1.2 $/bn 1.3 $/bn Non-Acute 65 $/mln 0.5 $/bn 183K 63 $/mln 79
Slide 80: The success of the specialty product strategy on LIAISON MDX
04 | MOLECULAR DIAGNOSTICS LIAISON MDX Plus The success of the “specialty product strategy” on LIAISON MDX Acute, complicated cases needs high-clinical value diagnostics that drive patient management. Diasorin expertise in specialty testing confirms its positioning in the marketplace Revenue growth
Slide 81: Diasorin will continue to expand in Specialty Testing
04 | MOLECULAR DIAGNOSTICS Future expansion in Specialty Testing Diasorin will continue to expand in Specialty Testing >10 plex Genetics Multiplexing capabilities 10 plex ~1.5 $/bn TAM Vector Borne ~110 $/mln TAM Fungal Infections 1-6 plex ~900 $/mln TAM Not our target WHO fungal priority pathogens
Slide 82: Diasorin portfolio positioning in the IDN evolving landscape
Diasorin portfolio positioning in the IDN evolving landscape
Slide 83: Key Takeaways on Molecular Diagnostics
04 | MOLECULAR DIAGNOSTICS Key Takeaways Key Takeaways on Molecular Diagnostics • Diasorin is executing on the Strategy to provide the right test for the right patient in the right setting • Diasorin is leader in syndromic customized testing • Technologies tailored to the different segments’ needs,
Slide 84: Licensed Technologies
05 LICENSED TECHNOLOGIES Angelo Rago
Slide 85: Licensed Technologies: Enabling Innovation & Value Creation
05 | LICENSED TECHNOLOGIES Market Environment Licensed Technologies: Enabling Innovation & Value Creation 2025 LTG Revenue & Segments Life Science Research • Basic Research • Applied Research Royalties on kit sales 38% 7% % Pharma • Drug Discovery FY’25 • Vaccines Development $ Diagnostics $$$ & Res
Slide 86: Diagnostics
05 | LICENSED TECHNOLOGIES Market Environment | Diagnostics Diagnostics Products Diagnostic Kits Diasorin serves diagnostic partners that create specialty applications Multi- Transplant Autoimmune pathogen Transplant diagnostics Autoimmune & ID Diagnostics Testing services (biomarker LDTs) IVD Instr
Slide 87: Life Science Research
05 | LICENSED TECHNOLOGIES Market Environment | Life Science Research Life Science Research Products Research Use Only Kits Diasorin serves Life Science partners who provide Quantitative Gene Biomarker ready-to-use multi-analyte panels to power pharma Proteomics Expression Panels discovery and acade
Slide 88: Pharma
05 | LICENSED TECHNOLOGIES Market Environment | Pharma Pharma Products RUO Kits & Ingredients for GLP Assays Diasorin enables pharmaceutical companies to develop Drug Discovery Multivalent Vaccines specialty and proprietary assays for drug and vaccine development Assay Kits Microspheres Assay Suppor
Slide 89: Key Takeaways on Licensed Technologies
05 | LICENSED TECHNOLOGIES Key Takeaways Key Takeaways on Licensed Technologies Revenue base Diversified business model Highly recurring and high-quality Diagnostics, Life Science Research and Pharma Exposure to multiple end- markets • Diagnostics: stable and profitable core (growth in line with the
Slide 90: ESG & Financials
06 ESG & FINANCIALS Alberto Donati
Slide 91: ESG
E S G Sma ( PASSIONE PER IA ( PASSIONE a SCIENZA, PER LA SCIENZA PERL ; 3 LEGS : ft tigers H : | 4. fe: aly Pes h a" . \ y
Slide 92: ESG 2026-2030
06 | ESG & FINANCIALS ESG ESG 2026-2030 OBJECTIVES KPIs E Improve Group’s energy efficiency -600 tons of CO₂ in industrial sites by 2030 Strengthen Diversity & Inclusion 100% of employees trained on D&I Enhance employee wellbeing ≥80% of Group employees covered by employee assistance programs S Prom
Slide 93: Financials
FINANCIALS
Slide 94: Guidance @CER: Total Revenues
06 | ESG & FINANCIALS Guidance | Total Revenues Guidance @CER*: Total Revenues +6% / +8% CAGR +5% / +6% 2025 A 2026 Estimate 2030 Estimate * In order to allow comparability across years, all financials' data have been restated at constant exchange rate (with regard to the U.S. dollar 1.20 USD per EU
Slide 95: Revenues By Technology @CER
06 | ESG & FINANCIALS Guidance | Revenues by Technology Revenues By Technology @CER* +6% / +8% Licensed Technologies CAGR Molecular Diagnostics Low-to-Mid Single Digit Immunodiagnostics Increase +5% / +6% LIAISON NES > 150 $/mln in the U.S. market Low-to-Mid Single High Teens Increase Digit Increase
Slide 96: Revenues By Geography @CER
06 | ESG & FINANCIALS Guidance | Revenues by Geography Revenues By Geography @CER* +6% / +8% Rest of the World CAGR Europe Mid-to-High Single Digit North America Increase +5% / +6% Low-to-Mid Single Digit Increase Flat Low-to-Mid Single Digit Increase Low Double Digit Increase High Single Digit Incr
Slide 97: Revenues Evolution: from 2026 to 2030
06 | ESG & FINANCIALS Guidance | Revenues Evolution Revenues Evolution: from 2026 to 2030 BY TECHNOLOGY 13% 10% Immunodiagnostics Immunodiagnostics 17% Molecular Diagnostics 2026 Licensed Technologies 2030 30% Molecular Diagnostics Licensed Technologies 60% 70% BY GEOGRAPHY 13% 10% Rest of the World
Slide 98: Guidance: Adjusted EBITDA Margin and Free-Cash-Flow
06 | ESG & FINANCIALS Guidance | Adjusted EBITDA Margin and Cumulated FCF Guidance @CER*: Adjusted** EBITDA Margin and Free-Cash-Flow Cumulated FCF*** over 4 years Adjusted EBITDA Margin (2027-2030) ca. +200 bps 34% - 35% ~ 1 €/bn 32% 32% - 33% / 33% 34% / 35% 2026 Estimate 2030 Estimate * In order
Slide 99: Capital Allocation Strategy
06 | ESG & FINANCIALS Capital Allocation Strategy Strong Operating Cash Flow Generation and Disciplined Capital Deployment to Maximise Shareholder Value FY 23-26 FY 27-30 Investment Amount / % of Total % of Total 1 Organic Growth Continue investing in the business in support of long-term organic gro
Slide 100: Key Takeaways
O7 3 KEY TAKEAWAYS Carlo Rosa CEO
Slide 101: Looking Forward to 2030: what do we commit to deliver
07 | KEY TAKEAWAYS Looking Forward to 2030: what do we commit to deliver Immunodiagnostics Molecular Diagnostics Licensed Technologies >20 new assays to cover Increasing competitiveness of LIAISON Increasing revenue opportunity through Autoimmunity, GI and ID specialties NES, expanding in women’s he
Slide 102: Q&A
08 Q&A Carlo Rosa Alberto Donati
Slide 103: Slide 103